Core Insights - RxSight, Inc. reported a total revenue of $30.3 million for Q3 2025, a decrease of 14% compared to $35.3 million in Q3 2024, with a notable increase in Light Adjustable Lens (LAL) revenue by 6% and a significant decrease in Light Delivery Device (LDD) revenue by 69% [5][9] - The company experienced a net loss of $(9.8) million, or $(0.24) per share, compared to a net loss of $(6.3) million, or $(0.16) per share in the same quarter of the previous year [8][9] - Gross profit for Q3 2025 was $24.2 million, representing 80% of revenue, an increase from 71% in Q3 2024, primarily due to a favorable product mix shift towards LAL sales [6][9] Financial Highlights - Total revenue for Q3 2025 was $30.3 million, down 14% from $35.3 million in Q3 2024 [5][9] - Gross profit was $24.2 million, or 80% of revenue, compared to $25.2 million, or 71% of revenue in Q3 2024 [6][9] - Operating expenses increased by 6% to $36.4 million from $34.4 million in Q3 2024, reflecting ongoing investments in LAL sales and R&D [7][9] - The company reported an adjusted net loss of $(1.7) million, or $(0.04) per share, compared to an adjusted net gain of $0.2 million, or $0.01 per share in Q3 2024 [8][9] Strategic Highlights - The company noted a stabilization and recovery in procedure trends, with increased engagement from surgeons observed at major ophthalmic conferences [4] - RxSight has realigned its U.S. commercial organization to enhance customer relationships and drive growth in LAL procedures [9] - The company launched new practice development and clinical engagement programs aimed at sharing insights from over 250,000 LAL cases [9] Guidance - The company narrowed its full-year 2025 revenue guidance to a range of $125.0 million to $130.0 million, reflecting an implied decrease of 11% to 7% compared to 2024 [14] - Gross margin guidance was raised to a range of 76% to 77%, an increase from the previous range of 72% to 74% [14] - Operating expenses are projected to remain between $145.0 million and $155.0 million, indicating an implied increase of 7% to 14% compared to 2024 [14]

Core Insights - RxSight, Inc. will participate in the American Academy of Ophthalmology Annual Meeting (AAO 2025) with multiple Live Learning Sessions showcasing the Light Adjustable Lens technology [1][2] Company Overview - RxSight, Inc. specializes in ophthalmic medical devices aimed at providing customized vision solutions for patients post-cataract surgery [5] - The RxSight Light Adjustable Lens system is the first and only commercially available intraocular lens technology that can be adjusted after surgery, allowing for personalized vision correction [5] Live Learning Sessions Details - The sessions will feature insights from leading surgeons on the clinical advantages and economic impact of the Light Adjustable Lens [2] - A schedule of sessions includes topics such as ROI, career development, clinical confidence, and patient-centered outcomes, with various experts presenting on October 18 and 19 [3][4]

Company Overview - RxSight, Inc. is an ophthalmic medical device company focused on providing high-quality customized vision for patients after cataract surgery [3] - The company offers the RxSight Light Adjustable Lens system, which includes the RxSight Light Adjustable Lens (LAL/LAL+), Light Delivery Device (LDD™), and accessories, representing the first and only commercially available intraocular lens technology that can be adjusted post-surgery [3] Upcoming Events - RxSight's management is scheduled to present at the Bank of America Healthcare Conference in Las Vegas on May 14, 2025, at 3:40 p.m. Pacific Time / 6:40 p.m. Eastern Time [2] - A live and archived webcast of the presentation will be accessible for interested parties [2] Contact Information - Shelley B. Thunen serves as the Chief Financial Officer and can be contacted via email at sthunen@rxsight.com [4] - Oliver Moravcevic is the VP of Investor Relations and can be reached at omoravcevic@rxsight.com [4]